Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) Director Mark C. Mckenna acquired 20,000 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $49.54 per share, with a total value of $990,800.00. Following the purchase, the director now directly owns 20,000 shares in the company, valued at approximately $990,800. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Apogee Therapeutics Stock Performance
NASDAQ:APGE opened at $47.21 on Tuesday. The company has a market capitalization of $2.13 billion, a P/E ratio of -19.51 and a beta of 2.30. The stock's 50 day moving average price is $51.27 and its 200 day moving average price is $48.31. Apogee Therapeutics, Inc. has a 52 week low of $22.20 and a 52 week high of $72.29.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of APGE. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Apogee Therapeutics in the 3rd quarter valued at $71,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Apogee Therapeutics by 21.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company's stock worth $94,000 after buying an additional 285 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Apogee Therapeutics during the 2nd quarter worth about $143,000. Wexford Capital LP acquired a new position in shares of Apogee Therapeutics during the 3rd quarter valued at about $230,000. Finally, Intech Investment Management LLC bought a new position in shares of Apogee Therapeutics in the 3rd quarter valued at approximately $300,000. Institutional investors and hedge funds own 79.04% of the company's stock.
Analyst Upgrades and Downgrades
Amazon coin set to soar 25X – starting December 16th?
From True Market Insiders | Ad
This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon.
And one team of crypto experts has identified it as the most promising crypto of 2024.
You can see all of the details surrounding the #1 Crypto of 2024
>3-Cent Amazon Coin<
Several brokerages have recently commented on APGE. Canaccord Genuity Group started coverage on Apogee Therapeutics in a research report on Monday, November 25th. They issued a "buy" rating and a $89.00 target price for the company. Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research note on Thursday, December 12th. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They issued a "buy" rating and a $89.00 price target for the company. Finally, Wedbush boosted their price objective on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an "outperform" rating in a research report on Monday, December 2nd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Apogee Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $83.88.
Check Out Our Latest Stock Analysis on Apogee Therapeutics
About Apogee Therapeutics
(
Get Free Report)
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
